NervGen Pharma

CVE:NGEN · CA64082X2032

PharmaceuticalsX-Small

360° View

Value94

Price/Sales—

Price/Earnings76

Price/Book95

Dividend Yield1

Growth53

Revenue Growth—

Profit Growth54

Capital Growth89

TSR 52w20

Safety42

Leverage30

Liquidity86

Refinancing22

Combined67

Sentiment11

Analyst Opinions30

Pro Holdings5

Opinion Changes9

Market Pulse75

Profile

CountryCanada

IndustryPharmaceuticals

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2017

Employees9

Websitenervgen.com

ISINCA64082X2032

Last UpdateApr 2, 2026

Index & Theme

NeurologyCentral Nervous SystemNeuroscienceBiotechnology

Description

NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company primarily operates in the biotechnology sector, dedicated to advancing…

Analysis

NervGen Pharma's 360° View rank of 44 places it below its peer average — better than 44% of its true peers.

It's growing solidly (53) and looks cheap versus peers (94). On safety it is carrying more balance-sheet risk (42), and the market shows skeptical sentiment (11). Taken together, its Combined rank of 67 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare NervGen Pharma with its peers

CalciMedica

NAQ:CALC

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Neumora Therapeutics

NSQ:NMRA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Nektar

NAQ:NKTR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Structure Therapeutics

NMQ:GPCR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MIRA Pharmaceuticals

NAQ:MIRA

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Trevi Therapeutics

NMQ:TRVI

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →